MENU

Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda

The drugmaker raised its full-year sales forecast to $63.4 billion to $64.4 billion on increased demand for key products, particularly oncology treatments.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story